Corporate Update on Ascentage Pharma Group

Ascentage Pharma Group International (ticker: 6855.HK) concluded its most recent trading session with a modest gain of 2.29 % on Thursday, 22 October 2026. The share closed at approximately HKD 28.50 on the Hong Kong Stock Exchange, reflecting a healthy liquidity profile with 359.6 million shares outstanding and a market capitalization of HKD 11.2 billion. In the last 24 hours, the stock traded at a volume of roughly HKD 58.5 million, a figure that sits comfortably below its 200‑day simple moving average of HKD 40.23. The most recent 52‑week high and low—HKD 69.95 on 27 October 2025 and HKD 27.12 on 9 October 2026, respectively—underscore the breadth of the company’s price volatility over a full year.

Breakthrough Therapy Designation

On 20 October 2026, Ascentage Pharma Group announced that its BCL‑2 inhibitor, lisaftoclax, when combined with acalabrutinib, had received a Breakthrough Therapy Designation from China’s National Medical Products Administration (NMPA). This designation is intended to accelerate regulatory communication and expedite the development timeline for the therapy, specifically for the treatment of previously untreated chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL). The company already holds approval in China for lisaftoclax in patients who have undergone prior systemic therapy, and it is currently conducting multiple Phase‑III studies—including a pivotal trial evaluating the combination as first‑line therapy. The designation signals a clear expansion of the company’s therapeutic portfolio and a reinforcement of its strategy to deliver novel treatment options to patients with hematologic malignancies.

Market Context and Peer Activity

The performance of Ascentage Pharma Group should be viewed alongside the recent activity of several related stocks:

  • Beijing Aosaikang Pharm (002755.SZ) remained flat, trading at CNY 11.79 with a market capitalization of CNY 11.4 billion and a price‑to‑earnings ratio of 151.8.
  • Quick Intelligent Equipment (603203.SS) also traded unchanged, priced at CNY 33.39, with a market cap of CNY 11.4 billion and a P/E of 80.79.
  • Information Tech (300229.SZ) showed a modest rise, reflecting a broader uptick in the electronic identification sector. The company maintained a stable position relative to its peers, with institutional inflows suggesting a cautious optimism.
  • Consun Pharmaceutical (1681.HK) experienced a 2 % decline, closing at HKD 15.21, while its market capitalization remains at HKD 13.5 billion and its P/E ratio stands at 9.64.
  • Vigonvita Life Sciences –H (2630.HK) traded flat at HKD 76.55, with a market capitalization of HKD 13.4 billion.

These peer movements illustrate a market that is largely range‑bound for the day, with Ascentage Pharma Group’s performance standing out as a relative gain in a context of broader stability.

Company Profile

Headquartered in Suzhou, China, Ascentage Pharma Group International is a clinical‑stage biotechnology company focused on the development of novel therapies for cancers, hepatitis B virus, age‑related diseases, and other conditions. The company operates across China, the United States, and other jurisdictions, leveraging its global footprint to accelerate drug development and commercialization. Ascentage Pharma Group is listed on the Hong Kong Stock Exchange and maintains an active presence through its website at www.ascentagepharma.com .